Pharmacokinetic Differences, Clinical Context and MediPharm’s Process Expertise

Gastric acid has long been recognised as a key factor in the physiology of the upper gastrointestinal tract, playing essential roles in protein digestion, mineral absorption and providing a natural defense against bacterial infections to a certain degree. However, inappropriate levels of gastric acid underlie several widespread pathologies, including gastroesophageal reflux disease and peptic ulcers, which cause pain and suffering in millions of people and, just a couple of decades ago, could be life-threatening if left untreated. Treatment options then, however, were limited. For example, for peptic ulcers, the main treatment was administration of antacids to neutralise excess gastric acid, but this provided only temporary relief. The alternative was an operation, which could, however, have serious side effects. Pharmacological control of the complex mechanism of gastric acid secretion has therefore long been desirable.

Over the following decades, pharmacological strategies evolved from simple acid neutralisation to inhibition of acid secretion itself, first through histamine H₂-receptor antagonists, which reduced acid output by blocking histamine-stimulated parietal cell activity, then through  discovery and development of proton pump inhibitors, which provided a far more potent and sustained suppression of gastric acid secretion. Omeprazole, prime drug of this group, was found to be significantly superior to previous treatment regimens of H₂-receptor antagonists in patients with

duodenal and gastric. On the basis of these discoveries, omeprazole was launched as the first line therapy for the mentioned diseases in Europe in 1988.

Esomeprazole, the S-isomer of omeprazole, was introduced to the market by AstraZeneca in 2001 under the trade name Nexium, shortly before the patent expiration of omeprazole.

Omeprazole contains a chiral sulfur atom in the sulfoxide moiety, giving rise to two optical isomers, the R- and S-forms. Esomeprazole represents the optically pure S-enantiomer, which was developed under the rationale that its pharmacokinetic profile could offer greater clinical consistency between individuals. The chiral switch to esomeprazole was achieved by developing an enantioselective synthesis that directly yields the S-enantiomer rather than separating it from the finished racemate.

Although both enantiomers share an identical mechanism of action, i.e. irreversible inhibition of the H⁺/K⁺-ATPase in gastric parietal cells, differences arise in their hepatic metabolism, particularly their affinity toward cytochrome P450 2C19 (CYP2C19).

CYP2C19 is responsible for the oxidative metabolism of proton pump inhibitors. Genetic variations in this enzyme result in two distinct metaboliser phenotypes, namely poor and extensive, causing variable plasma drug levels. Esomeprazole exhibits reduced metabolic clearance via CYP2C19 compared to its R-form, resulting in higher systemic bioavailability, more stable plasma concentrations and sometimes prolonged acid suppression. These differences were the central pharmacokinetic justification for the single-enantiomer formulation.

Comparative clinical data, however, show that the magnitude of therapeutic improvement remains modest most of the time. In practice, the switch from omeprazole to esomeprazole can be viewed as an incremental optimisation rather than a groundbreaking therapeutic innovation. While esomeprazole offers reduced inter-individual pharmacokinetic variability and potentially more predictable acid control, both compounds remain therapeutically comparable when used at pharmacologically equivalent doses. Consequently, the scientific rationale for chiral switching relies primarily on formulation refinement and pharmacokinetic stabilisation, rather than on differences in pharmacodynamics or clinical efficacy.

The omeprazole-esomeprazole transition exemplifies how precise control over process optimisation can lead to meaningful, albeit sometimes incremental, improvements. MediPharm’sexpertise in GMP manufacturing, lyophilisation and formulation development provides an ideal foundation for producing prazole-based formulations and supporting similar innovation-driven projects in collaboration with industry partners.

Sources:

[1] Piñeiro, F.J. and Rogelio Alberto, F.A. (2022) ‘A case study of AstraZeneca’s Omeprazole/Esomeprazole chiral switch strategy’, Generics and Biosimilars Initiative Journal, 11(2), pp. 57–64. doi:10.5639/gabij.2022.1102.011.

[2] Olbe, L., Carlsson, E. and Lindberg, P. (2003) ‘A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole’, Nature Reviews Drug Discovery, 2(2), pp. 132–139. doi:10.1038/nrd1010.